Integra LifeSciences Announces Full Market Release for the Integra(R) Freedom Wrist Arthroplasty System
PLAINSBORO, N.J., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the full commercial release of the Integra® Freedom Wrist Arthroplasty System in the United States. The system, which is used in the treatment of wrist arthritis, has been successfully implanted in a limited release in 21 patients, during the summer months.
"The design features of the Freedom Wrist Arthroplasty System provide a major advancement in the treatment of more active patients with advanced wrist arthritis," said designing surgeon Dr. Brian Adams, Baylor College of Medicine, Houston, TX. "This unique system, including a more anatomic design and better bone fixation, offers a distinct alternative for patients to achieve pain relief while simultaneously maintaining desired wrist motion."
The Freedom Wrist features advanced implant design and enhanced instrumentation to aid in efficient and potentially more reproducible surgical results. The introduction of the Freedom Wrist rounds out one of the most comprehensive wrist arthritis solutions portfolio in the industry.
"The Integra Freedom Wrist Arthroplasty System complements and expands our upper extremity portfolio and offers our surgeons an advanced anatomic solution for wrist arthroplasty procedures. We believe this product is a natural addition to our portfolio and will add to our success and growth in this market," said Mark Augusti, CVP and President, Integra Orthopedics and Tissue Technologies. "This is an excellent example of Integra's commitment to design products that help limit uncertainty for surgeons."
The Integra® Freedom Wrist Arthroplasty System will be on display at the 69th Annual Meeting of the American Society for Surgery of the Hand (ASSH) in Boston from September 18-20, 2014. During the meeting, designing surgeons Brian Adams, MD and Randy Bindra, MD, FRSC will be conducting a demonstration of the system and sharing their experience in an industry forum taking place Friday, September 19 at 12:00 pm.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2013 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences:
Media
Gianna Sabella
609-936-2389
gianna.sabella@integralife.com
Investors
Angela Steinway
609-936-2268
angela.steinway@integralife.com